Entries by Max

Phase 2 OPTIMAS Trial: Optimal PSA-Triggered Intermittent Therapy for mHSPC

/in , , /by

This Phase II study (OPTIMAS trial) explores a novel approach to treating metastatic hormone-sensitive prostate cancer (mHSPC) through PSA-triggered intermittent therapy. Traditionally, men with mHSPC are managed with continuous androgen deprivation therapy (ADT) in combination with androgen receptor pathway inhibitors (ARPIs). This strategy has significantly extended survival but often leads to enduring side effects such […]

Self-Assembled Nano-PROTAC to Improve Targeted Therapy in Castration-Resistant Prostate Cancer

/in , /by

A new study published in Nature Signal Transduction and Targeted Therapy reports a major leap in the design of targeted cancer therapies through the development of an in vivo self-assembled nano-PROTAC (proteolysis targeting chimera) system capable of delivering dual-targeted degradation in castration-resistant prostate cancer (CRPC).​ PROTACs have reshaped the drug discovery landscape by inducing selective […]

Dual Enzyme Blockade Weakens Prostate Cancer Tumors and Enhances Treatment Effectiveness

/in /by

Researchers have identified two enzymes that serve as critical guardians of prostate cancer cell survival, opening new avenues for enhancing treatment outcomes in one of the most common cancers affecting men worldwide. The study, published in the Proceedings of the National Academy of Sciences, demonstrates that blocking these molecular chaperones can destabilize cancer cells and […]

Phase 3 Trial: Xaluritamig (AMG 509) Plus Abiraterone in mCRPC

/in , , /by

A large international Phase 3 clinical trial  is evaluating a new treatment combination for men with metastatic castration-resistant prostate cancer (mCRPC) who have not yet undergone chemotherapy (in castration resistant settings, prior chemo is allowed). The study is testing xaluritamig (AMG 509) together with abiraterone acetate against the investigator’s choice of standard therapies (docetaxel, cabazitaxel, […]

UPDATE: Phase 1 Trial of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

/in , , /by

A new Phase 1 clinical study, known as the ARTISAN trial, is evaluating an investigational lead-212 alpha radioligand therapy targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). We discussed AB001 in a previous article; the trial has now been approved, and its full details are available. The therapy combines a […]

Newsletter 41/2025

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! ​First of all, thank you! The target has been reached. Thanks to your donations, I can renew our subscription to Kit.com and keep sending the newsletters!​ This week we have a great mix of clinical and preclinical research, including […]